Pipetting robot for academic research - 28/08/2024 goodBot GmbH: a third arm for researchers Repetitive tasks that researchers have to conduct in the lab tend to be tiring and often lead to errors. Precise pipetting is crucial for achieving reproducible results. Automation is underrepresented in research labs and existing pipetting robots are unsuitable for scientists. This is why Dr. Julius Wiener, Tobias Zundel and Oliver Brunner decided to found the company goodBot GmbH and develop a pipetting robot tailored to academic research.https://www.gesundheitsindustrie-bw.de/en/article/news/goodbot-gmbh-third-arm-researchers
Event - 01/10/2024 Lunch & Learn: BW-UK Health Industry Procurement - Building Bridges for Better Healthcare Online, Registration deadline: 30/09/2024, Informationsveranstaltung https://www.bio-pro.de/en/events/lunch-und-learn-bw-uk-health-industry-procurement-building-bridges-better-healthcare
Event - 01/10/2024 Lunch & Learn: BW-UK Health Industry Procurement - Building Bridges for Better Healthcare Online, Registration deadline: 30/09/2024, Informationsveranstaltung https://www.gesundheitsindustrie-bw.de/en/event/lunch-und-learn-bw-uk-health-industry-procurement-building-bridges-better-healthcare
Event - 11/11/2024 - 15/11/2024 DigiHealthDay 2024 Deggendorf, Germany, Kongress/Symposium https://www.gesundheitsindustrie-bw.de/en/event/digihealthday-2024
Press release - 14/08/2024 New vaccine against cervical cancer combines prophylactic and therapeutic activities Scientists at the German Cancer Research Center (DKFZ) have developed a completely new vaccination concept. The vaccine is inexpensive and protects mice against almost all cancer-causing HPV types. In addition to preventing new infections, the vaccine also triggers cellular immune responses against HPV-infected cells and may therefore also have a therapeutic effect against existing infections.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-vaccine-against-cervical-cancer-combines-prophylactic-and-therapeutic-activities
Press release - 13/08/2024 Peptide Boronic Acids: New Prospects for Immunology A cutting-edge chemical process is the first to make it possible to quickly and easily produce modified peptides with boronic acids. As part of this work, scientists managed to synthesize a large number of different biologically active peptide boronic acids and investigate their properties. They open up new possibilities in the young research field of synthetic immunology and could go on to be used primarily in immunotherapy. https://www.gesundheitsindustrie-bw.de/en/article/press-release/peptide-boronic-acids-new-prospects-immunology
Start-up Cerebri GmbH - 05/08/2024 Comprehensive EEG supply thanks to telemedicine Fewer and fewer patients are getting timely access to electroencephalograms, as the process of measuring brain activity and interpreting the results requires specific expertise. Cerebri GmbH, a newly established Tübingen-based company, aims to address this issue by offering user-friendly EEG caps and providing rapid, location-independent and top-tier diagnostics by experts.https://www.gesundheitsindustrie-bw.de/en/article/news/comprehensive-eeg-supply-thanks-telemedicine
Press release - 01/08/2024 Targeted therapy for cancer of unknown primary (Cup) Encouraging results from a large international study led by Heidelberg have recently been published in the journal “Lancet”: The genetic material of cancer cells with unknown tissue of origin contains numerous targets for specific drugs that are already available and have been developed to treat other forms of cancer. These suppressed the disease in CUP patients for significantly longer than chemotherapy.https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeted-therapy-cancer-unknown-primary-cup
The start of a transnational cooperation for a future of sustainable healthcare - 25/07/2024 BIOPRO is a sustainability partner in the EU HACK-IT-NET project The HACK-IT-NET (“Health And Care Knowledge and Innovation Transfer NETwork”) project aims to provide holistic and seamless healthcare for all patients in the Alpine region. The project, which was launched in July 2024 and will run for three years, aims to bring together stakeholders in the healthcare sector to create a forward-looking healthcare ecosystem in the Alpine region. BIOPRO is a partner.https://www.bio-pro.de/en/information/press-release/biopro-sustainability-partner-eu-hack-it-net-project
Event - 20/11/2024 DIS&CO Health | Market opportunities in Morocco Online , Registration deadline: 19/11/2024, Informationsveranstaltung https://www.bio-pro.de/en/events/dis-und-co-health-marktchancen-marokko
Event - 20/11/2024 DIS&CO Health | Market opportunities in Morocco Online , Registration deadline: 19/11/2024, Informationsveranstaltung https://www.gesundheitsindustrie-bw.de/en/event/dis-und-co-health-marktchancen-marokko
Research association - 24/07/2024 SPI-MP: pioneer in personalised medical technology Every person is unique – even when they are ill. This is why many approaches to personalised medicine have been under development. The Stuttgart Partnership Initiative - Mass Personalization (SPI-MP), which focuses on basic research into fabrication and biomaterial technologies for personalised biomedical systems, is at the heart of such research work. The projects range from artificial knee joint cartilage to state-of-the-art stroke diagnostics.https://www.gesundheitsindustrie-bw.de/en/article/news/spi-mp-pioneer-personalised-medical-technology
Event - 07/11/2024 - 08/11/2024 Trinational HealthTech Days 2024 Breisach am Rheinhttps://www.gesundheitsindustrie-bw.de/en/event/trinational-healthtech-days-2024
Event - 03/12/2024 - 04/12/2024 MEDigIT 2024 Lille, France, Kongress/Symposium https://www.gesundheitsindustrie-bw.de/en/event/medigit-2024
Press release - 11/07/2024 Presentation of the DKFZ Innovation Award and DKFZ Patient Expert Award The "Friends of the German Cancer Research Center" association supports the DKFZ and aims to help strengthen its position in international competition. With the DKFZ Innovation Award presented at this year's DKFZ annual reception, the association honored Titus Brinker as a researcher whose highly innovative work builds a bridge from research to practical application with commercialization potential.https://www.gesundheitsindustrie-bw.de/en/article/press-release/presentation-dkfz-innovation-award-and-dkfz-patient-expert-award
Save the date - 28/11/2024 Meet & Match - Gender Medicine: Biological insights and healthcare advances Strasbourg (France) | CIARUS, Registration deadline: 27/11/2024, Meet & Match https://www.bio-pro.de/en/events/meet-und-match-gender-medicine-biological-insights-and-healthcare-advances
Save the date - 28/11/2024 Meet & Match - Gender Medicine: Biological insights and healthcare advances Strasbourg (France) | CIARUS, Registration deadline: 27/11/2024, Meet & Match https://www.gesundheitsindustrie-bw.de/en/event/meet-und-match-gender-medicine-biological-insights-and-healthcare-advances
Event - 26/08/2024 - 30/08/2024 Biotechgate Digital Partnering: Virtual business development & licensing event online, Informationsveranstaltung https://www.gesundheitsindustrie-bw.de/en/event/biotechgate-digital-partnering-virtual-business-development-und-licensing-event
Press release - 10/07/2024 HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds. The new funds of €15 million will be used to advance the clinical development of the clinical candidate HRX-215.https://www.gesundheitsindustrie-bw.de/en/article/press-release/heparegenix-raises-euro-15-million-series-c-round-advance-clinical-development-hrx-215-liver-regeneration
TWYCE GmbH - 10/07/2024 Better immune response against prostate cancer thanks to new bispecific antibodies TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/better-immune-response-against-prostate-cancer-thanks-new-bispecific-antibodies
Press release - 09/07/2024 Unique characteristics of previously unexplored protein discovered Freiburg-Prague research collaboration achieves scientific breakthrough in understanding cell division. The international research collaboration has uncovered a new mechanism of the crosstalk between microtubules and actin cytoskeleton during cell division and revealed unique characteristics of the previously unexplored protein FAM110A.https://www.gesundheitsindustrie-bw.de/en/article/press-release/unique-characteristics-previously-unexplored-protein-discovered
Press release - 05/07/2024 Outstanding ideas – new imaging processes for cancer diagnostics and nanopropellers for ocular gene therapy The summer reception hosted by BioRegio STERN Management GmbH has once again provided a fitting backdrop for the Science2Start award ceremony. Last Thursday, at Tübingen observatory, was the 15th time that scientists and start-up founders were celebrated for outstanding ideas that a panel of experts judged to have special economic potential.https://www.gesundheitsindustrie-bw.de/en/article/press-release/outstanding-ideas-new-imaging-processes-cancer-diagnostics-and-nanopropellers-ocular-gene-therapy
Press release - 05/07/2024 The Symphony of Organelles With "OrgaPlexing", scientists at the MPI of Immunobiology and Epigenetics have developed a new method that shows how guardian cells of the immune system, the macrophages, orchestrate their cell structures during inflammation or bacterial infection, making it possible to observe the interactions between several organelles simultaneously and thus providing insights into cell metabolism and the production of inflammatory molecules. https://www.gesundheitsindustrie-bw.de/en/article/press-release/symphony-organelles
Press release - 04/07/2024 Antibody can improve immune cell therapy against leukemia Scientists from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD) have shown that the combination of therapeutic immune cells, known as CAR T cells, and a bispecific antibody could improve the treatment of leukaemia. In the culture dish and in mice, they tested CAR-T cells directed against the B-cell marker CD19 in combination with bispecific antibodies that bind to the B-cell-specific protein CD20. https://www.gesundheitsindustrie-bw.de/en/article/press-release/antibody-can-improve-immune-cell-therapy-against-leukemia
Event - 03/12/2024 - 04/12/2024 MedFit 2024 Lille, France, Kongress/Symposium https://www.gesundheitsindustrie-bw.de/en/event/medfit-2024